Strategic Mastery in Latin America: A Unique Business Model
The company follows an asset-light strategy, sourcing 60% of its formulations from China while directly exporting to the bottom end of the pyramid in Latin American countries. By strategically placing warehouses near customers, they eliminate middlemen, ensuring cost efficiency and better market penetration. They have successfully navigated a challenging geography where many struggle to operate. Additionally, the elder son of the CEO is married in Latin America, further strengthening the company’s deep-rooted presence and understanding of the region.
Neoethicals Chile SpA operates in Chile in the
Pharmaceutical Marketing and Distribution business.
Neoethicals Chile SpA was incorporated by public
deed on 31st March, 2015. It primarily serves the
Chilean market. The turnover of Neoethicals Chile
SpA for the last three years is as follows:
CY 2024 – Chilean Peso 278,565,412 (US$ 295,222)
CY 2023 – Chilean Peso 49,995,906 (US$ 59,585)
CY 2022 – Chilean Peso Nil
Neoethicals Chile SpA had distributed the products of
Caplin Point Laboratories Limited in the Chilean
market and hence the acquisition was made at face
value to make Neoethicals Chile SpA a Subsidiary of
the Company. This is a strategic investment reflecting
our long-term confidence in our business model and growth potential
As per the report above turnover was US$ 295,222 for FY 2024, if they bought the whole company for the same amount, it was damn cheap, but I would be skeptical if it actually was bought for just 300K USD
Acquisition cost is mentioned in the PDF you attached. It is just 3K USD. It is a distribution company, turnover has no relevance in calculating the worth of company.
I am holding this company for the last 5 years and it had given me 6x returns. I like the consistency in their performance. They were able to grow at 15-20% consistently for the last 5 years. I hope this growth will continue in the coming years as well. They are expanding into US market, but not sure whether they will be successful. They are quite successful in South American market. Management is highly transparent and clean. Recently FIIs have increased their holding which is a good sign. Available at reasonable valuation of 27 even though median valuation is at 20. But considering future growth prospects and PE rerating happened because of FIIs, we can still look at this company.
This company performing such consistently over the years, with such high margins, that it is almost unbelievable. If we see Company performance for the last 11 years, in every year it has shown a growth in revenue and profits at the rate 18-20%. Not a single bad year, even during and after Covid also the Company grew nicely. It has almost like a perfect numbers. Consistent growth with no cyclicity, high Margins, high ROCE and ROE and good FCF generation.
Why then such a company, does not have any specific moat? Why PE of the company is 28, and median PE over last 10 years is only 22. PE of Divis lab is 80 with much less consistent performance. Why still the FII and DII holding in the company so low?
Am I missing something here…??
I have the exact same question. Such consistency is actually a bit scary but then, even cash flow seem right and there is nothing seem to be wrong.
Other than its a small business and maybe, unregulated market risk, I do not understand why big money is not flowing in more than it has. Like a year or 2 back, there was no institutional money and now some small amount. It could be because that promoters are not willing to sell, not sure.
I can only imagine that - If they pull off US business and scale in a year or 2, then rerating is for sure.
We can only analyze the numbers and appreciate the management for what they have done. If anybody has read/heard 2-3 concalls of the management, you’ll know their brilliance. Their clarity, focus on sustainable growth, cost efficiencies, having a unique end-to-end business model and most importantly, focus on bottom line and cash flows.
Why market isn’t paying very high valuations or when it will pay a high valuation (Current valuations are very fair) is not a relevant question i feel for a long term investor. As long as they keep growing steadily and maintain the robustness of their business model, Its the only thing we need to be concerned with. Markets will move when it wants to move
DISCLOSURE: Invested. One of the core holdings of the portfolio. But without doubt my favorite company and management. Hence, BIASED.
I agree Numbers are exceptional. But my point is what is their moat, which supports this performance. Company’s 82% revenue comes from Latin America. 75% of business comes from Generics.
They do not have manufacturing moat, as 50% of their products are outsourced. They do not have any brands. So they are licensing their generic products and selling in Latin American markets. Agreed that they have a good distribution network in Latin America, but is that, such a big moat, which nobody else can crack for last 10-15 years. And why 33% ebitda margin by selling generic products.
Since you are tracking the company closely, you may be able to throw some light..
One of the strongest moats consistently highlighted by the CEO in every earnings call is the company’s commitment to taking the road less travelled. They have carved a niche by focusing on markets at the bottom of the pyramid—geographies that big pharma companies often avoid due to physical, logistical, and operational risks. Caplin has boldly entered these underserved regions, building deep distribution networks where competition is minimal.
A significant catalyst in their Latin American success has been the CEO’s elder son, who, through personal and professional connections (including marriage in the region), has helped transform Caplin into a recognized brand—not just a generic supplier. For over 21 years, they’ve built a solid reputation in these markets.
Their high margins in the generics segment stem from a strategic blend of being asset-light and maintaining direct access to end consumers. By placing warehouses in close proximity to customers, they have effectively removed intermediaries, driving operational efficiency and cost advantages.
What further sets them apart is their disciplined approach to free cash flow management, meaningful capex deployment, and maintaining a zero-debt balance sheet along with a consistent sales and profit growth from last 12 years . Additionally, the clear delegation of responsibilities within the promoter family—the elder son handling Latin America, the younger son focusing on the US market, and the CEO overseeing production in India—strengthens operational execution.
As their US business scales up, Caplin is likely to undergo a re-rating and attract interest from larger institutional investors and fund houses.
In Formulations where product registration takes 6-18 months, changing supplier is not easy. Thus getting your products from 3rd Party puts your model at great risk not only from supply but also from Quality Control perspective. (Which is not in your direct control). Also central America is a very risky market to operate (But by local presence like warehouses, field force for sales this can be mitigated to a large extent).
Margins are generally high in pharma and esp in complex products like injectables & Opthalmic products.
So from DII/FII perspective when you are getting top Indian pharma MNC at 25-30 PE, why bother about Caplin?
Caplin has MOAT because it manufactures generic medicines from the backend and tries to minimize their cost so it can earn a good margin.
And the second thing in a generic business is not only the supply chain but the supply & demand mechanism that works, which creates the price. and management knew how to capture demand and get maximum benefit from it. for eg
